New in Small Molecule Therapeutics from the September issue—MEK Inhibition Enhances the Antitumor Effect of #Radiotherapy in #NF1-Deficient #Glioblastoma. bit.ly/3XmdHMf Maria Ioannou Dr. Schreck Abiola Christine Pratilas MD Johns Hopkins Kimmel Cancer Center Johns Hopkins Neurosurgery

New in Small Molecule Therapeutics from the September issue—Combination Immunotherapy with Vaccine and Oncolytic HSV Virotherapy Is Time Dependent. bit.ly/47pjsxi Sam Gary, PhD L Peruzzotti-Jametti Joshua Bernstock UAB MSTP Cambridge University Brigham and Women's Neurosurgery

Beautiful work by Dr. Schreck and team and an important step forward for NF1-associated HGG. Congrats!

New in Large Molecule Therapeutics from the September Issue—MYTX-011: A pH-Dependent Anti–c-MET Antibody–Drug Conjugate Designed for Enhanced Payload Delivery to c-MET–Expressing Tumor Cells. bit.ly/3ZlTKYz Brian Fiske #openaccess

Congrats to our team Boehringer Ingelheim for publishing our latest research on targeting #MDM2 in MCT Molecular Cancer Therapeutics AACR Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules aacrjournals.org/mct/article/do…

New in Large Molecule Therapeutics from the September Issue—HPN328, a Trispecific T Cell–Activating Protein Construct Targeting #DLL3-Expressing #SolidTumors. bit.ly/3XELzW6 #openaccess

Don't miss the interview with the recipient of the 2024 Molecular Cancer Therapeutics Award for Outstanding Journal Article—George Zhang, PhD. bit.ly/4eFqYXF

New in Large Molecule Therapeutics from the September Issue—IL-15/IL-15Rα-Fc-Fusion Protein XmAb24306 Potentiates Activity of CD3 #BispecificAntibodies through Enhancing T-Cell Expansion. bit.ly/3XpV8H7 Genentech

New in Large Molecule Therapeutics from the September Issue—Enhancing Neutrophil #Cytotoxicity of a Panel of Clinical #EGFR Antibodies by Fc Engineering to IgA3.0. bit.ly/4e6SBbV UMC Utrecht Universität Kiel CAU 🎓 Universitätsklinikum Schleswig-Holstein

Have a new drug candidate whose structure has not been previously reported in the literature? Consider submitting your study as a First Disclosure article, which extends to all drug categories—including cellular therapies. bit.ly/3XveZVp

New in Targeting Drug Resistance from the September Issue—Combining EHMT and PARP Inhibition: A Strategy to Diminish Therapy-Resistant #OvarianCancer Tumor Growth while Stimulating Immune Activation. bit.ly/3BaOGfR CU Cancer Center CU OB-GYN Education @lilynnguyen Edward Chuong

New in Companion Diagnostic, Pharmacogenomic, and Cancer Biomarkers from the September Issue—Prognostic Significance of SASP-Related Gene Signature of #RadiationTherapy in #HNSCC. bit.ly/3Bb89Nl

Molecular Cancer Therapeutics is seeking a new Editor-in-Chief! Apply by September 30, 2024. Find out more: bit.ly/4eN7Jvl

Preclinical Evaluation of DS-7300a, a Novel Anti–B7-H3 ADC—read this article by Michiko Yamato et al., featured in the AACR Journals Collection on Developmental Therapeutics. bit.ly/47PWXCh #openaccess

Read highlights of selected articles from the September issue. bit.ly/4gAyogC

Check out the AACR journal articles published concurrently with presentations during #AACR24. bit.ly/3ZtSwe5

#ICYMI: Pretargeted #Radioimmunotherapy with the Novel Anti-oxMIF/HSG Bispecific Antibody ON105 Results in Significant Tumor Regression in Murine Models of Cancer. bit.ly/3ZBcSSO OncoOne Friedmund Bachmann #openaccess #FirstDisclosure

#ICYMI: A Senescence-Mimicking (Senomimetic) VEGFR TKI Side Effect Primes Tumor Immune Responses via IFN/STING Signaling. bit.ly/4djIG1u @eboslab @Sbenzekry ACS Research Department of Cancer Genetics and Genomics Roswell Park

#OnlineFirst: A B7-H3-targeted CD28 #BispecificAntibody enhances the activity of anti-PD1 and CD3 #TcellEngager immunotherapies. bit.ly/3XTGdq2 #FirstDisclosure #openaccess

#ICYMI—MYTX-011: A pH-Dependent Anti–c-MET Antibody–Drug Conjugate Designed for Enhanced Payload Delivery to c-MET–Expressing Tumor Cells. bit.ly/4dmOo2N Brian Fiske #openaccess